Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis
Latest Information Update: 13 Mar 2025
At a glance
- Drugs SFA 002 (Primary) ; Apremilast
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors SFA Therapeutics
Most Recent Events
- 11 Mar 2025 New trial record